Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
Yes
Carmot Clinical Research Unit 101
Chula Vista, California, United States
Start Date
March 21, 2023
Primary Completion Date
March 6, 2024
Completion Date
April 6, 2024
Last Updated
December 27, 2024
32
ACTUAL participants
CT-868
DRUG
Placebo
DRUG
Victoza
DRUG
Lead Sponsor
Carmot Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07455994